Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. - Clowse MEB; Isenberg DA; Merrill JT; Dörner T; Petri M; Vital EM; Morand EF; Touma Z; Askanase AD; Ioannou Y; Brookes S; Gaiha-Rohrbach J; et al. (Lancet (London, England), 2026)